|
1
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hartwig W, Werner J, Jäger D, Debus J and
Büchler MW: Improvement of surgical results for pancreatic cancer.
Lancet Oncol. 14:e476–e485. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Galsky MD, Dritselis A, Kirkpatrick P and
Oh WK: Cabazitaxel. Nat Rev Drug Discov. 9:677–678. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Seruga B and Tannock IF:
Chemotherapy-based treatment for castration-resistant prostate
cancer. J Clin Oncol. 29:3686–3694. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dorff TB and Quinn DI: Cabazitaxel in
prostate cancer: Stretching a string. Lancet. 376:1119–1120. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kotsakis A, Matikas A, Koinis F,
Kentepozidis N, Varthalitis II, Karavassilis V, Samantas E,
Katsaounis P, Dermitzaki EK, Hatzidaki D, et al: A multicentre
phase II trial of cabazitaxel in patients with advanced
non-small-cell lung cancer progressing after docetaxel-based
chemotherapy. Br J Cancer. 115:784–788. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen R, Cheng Q, Owusu-Ansah KG, Chen J,
Song G, Xie H, Zhou L, Xu X, Jiang D and Zheng S: Cabazitaxel, a
novel chemotherapeutic alternative for drug-resistant
hepatocellular carcinoma. Am J Cancer Res. 8:1297–1306.
2018.PubMed/NCBI
|
|
9
|
Zhong T, He B, Cao HQ, Tan T, Hu HY, Li YP
and Zhang ZW: Treating breast cancer metastasis with
cabazitaxel-loaded polymeric micelles. Acta Pharmacol Sin.
38:924–930. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kunos CA, Stefan T and Jacobberger JW:
Cabazitaxel-induced stabilization of microtubules enhances
radiosensitivity in ovarian cancer cells. Front Oncol. 3:2262013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Abidi A: Cabazitaxel: A novel taxane for
metastatic castration-resistant prostate cancer-current
implications and future prospects. J Pharmacol Pharmacother.
4:230–237. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang Y, Bteich J and Li SD: Current update
of a carboxymeth-ylcellulose-PEG conjugate platform for delivery of
insoluble cytotoxic agents to tumors. AAPS J. 19:386–396. 2017.
View Article : Google Scholar
|
|
13
|
Baldwin AS Jr: The NF-kappa B and I kappa
B proteins: New discoveries and insights. Annu Rev Immunol.
14:649–683. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Karin M, Cao Y, Greten FR and Li ZW:
NF-kappaB in cancer: From innocent bystander to major culprit. Nat
Rev Cancer. 2:301–310. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Awasthee N, Rai V, Chava S, Nallasamy P,
Kunnumakkara AB, Bishayee A, Chauhan SC, Challagundla KB and Gupta
SC: Targeting IκappaB kinases for cancer therapy. Semin Cancer
Biol. 56:12–24. 2019. View Article : Google Scholar
|
|
16
|
Rajagopal C, Lankadasari MB, Aranjani JM
and Harikumar KB: Targeting oncogenic transcription factors by
polyphenols: A novel approach for cancer therapy. Pharmacol Res.
130:273–291. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zaidi AH, Raviprakash N, Mokhamatam RB,
Gupta P and Manna SK: Profilin potentiates chemotherapeutic agents
mediated cell death via suppression of NF-κB and upregulation of
p53. Apoptosis. 21:502–513. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li Q, Yang G, Feng M, Zheng S, Cao Z, Qiu
J, You L, Zheng L, Hu Y, Zhang T, et al: NF-κB in pancreatic
cancer: Its key role in chemoresistance. Cancer Lett. 421:127–134.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Das KC and White CW: Activation of
NF-kappaB by anti-neoplastic agents. Role of protein kinase C. J
Biol Chem. 272:14914–14920. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Perera PY, Qureshi N and Vogel SN:
Paclitaxel (Taxol)-induced NF-kappaB translocation in murine
macrophages. Infect Immun. 64:878–884. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Natarajan K, Singh S, Burke TR Jr,
Grunberger D and Aggarwal BB: Caffeic acid phenethyl ester is a
potent and specific inhibitor of activation of nuclear
transcription factor NF-kappa B. Proc Natl Acad Sci USA.
93:9090–9095. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
23
|
Mohammed S, Van Buren G II and Fisher WE:
Pancreatic cancer: Advances in treatment. World J Gastroenterol.
20:9354–9360. 2014.PubMed/NCBI
|
|
24
|
Lin QJ, Yang F, Jin C and Fu DL: Current
status and progress of pancreatic cancer in China. World J
Gastroenterol. 21:7988–8003. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hagmann W, Faissner R, Schnölzer M, Löhr M
and Jesnowski R: Membrane drug transporters and chemoresistance in
human pancreatic carcinoma. Cancers (Basel). 3:106–125. 2010.
View Article : Google Scholar
|
|
26
|
Lu Z, Kleeff J, Shrikhande S, Zimmermann
T, Korc M, Friess H and Büchler MW: Expression of the
multidrug-resistance 1 (MDR1) gene and prognosis in human
pancreatic cancer. Pancreas. 21:240–247. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ezrahi S, Aserin A and Garti N: Basic
principles of drug delivery systems - the case of paclitaxel. Adv
Colloid Interface Sci. 263:95–130. 2019. View Article : Google Scholar
|
|
28
|
Di Lorenzo G, Buonerba C, Autorino R, De
Placido S and Sternberg CN: Castration-resistant prostate cancer:
Current and emerging treatment strategies. Drugs. 70:983–1000.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zeng YY, Zeng YJ, Zhang NN, Li CX, Xie T
and Zeng ZW: The preparation, determination of a flexible complex
liposome co-loaded with cabazitaxel and β-elemene, and animal
pharmacodynamics on paclitaxel-resistant lung adenocarcinoma.
Molecules. 24:242019. View Article : Google Scholar
|
|
30
|
Vrignaud P, Sémiond D, Lejeune P, Bouchard
H, Calvet L, Combeau C, Riou JF, Commerçon A, Lavelle F and Bissery
MC: Preclinical antitumor activity of cabazitaxel, a semisynthetic
taxane active in taxane-resistant tumors. Clin Cancer Res.
19:2973–2983. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Villanueva C, Bazan F, Kim S, Demarchi M,
Chaigneau L, Thiery-Vuillemin A, Nguyen T, Cals L, Dobi E and Pivot
X: Cabazitaxel: A novel microtubule inhibitor. Drugs. 71:1251–1258.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang CY, Mayo MW and Baldwin AS Jr: TNF-
and cancer therapy-induced apoptosis: Potentiation by inhibition of
NF-kappaB. Science. 274:784–787. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen
LZ, Sheng H, Mo HY, Zeng JB, Deng W, et al: Melatonin overcomes
gemcitabine resistance in pancreatic ductal adenocarcinoma by
abrogating nuclear factor-κB activation. J Pineal Res. 60:27–38.
2016. View Article : Google Scholar
|
|
34
|
Qiao Q, Sun C, Han C, Han N, Zhang M and
Li G: Endoplasmic reticulum stress pathway PERK-eIF2α confers
radioresistance in oropharyngeal carcinoma by activating NF-κB.
Cancer Sci. 108:1421–1431. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Peng J, Hamanishi J, Matsumura N, Abiko K,
Murat K, Baba T, Yamaguchi K, Horikawa N, Hosoe Y, Murphy SK, et
al: Chemotherapy induces programmed cell death-ligand 1
overexpression via the nuclear factor-κB to foster an
immuno-suppressive tumor microenvironment in ovarian cancer. Cancer
Res. 75:5034–5045. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu J, Omene C, Karkoszka J, Bosland M,
Eckard J, Klein CB and Frenkel K: Caffeic acid phenethyl ester
(CAPE), derived from a honeybee product propolis, exhibits a
diversity of anti-tumor effects in pre-clinical models of human
breast cancer. Cancer Lett. 308:43–53. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Park MH, Kang DW, Jung Y, Choi KY and Min
S: Caffeic acid phenethyl ester downregulates phospholipase D1 via
direct binding and inhibition of NFκB transactivation. Biochem
Biophys Res Commun. 442:1–7. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
de Bono JS, Oudard S, Ozguroglu M, Hansen
S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L,
et al: TROPIC Investigators: Prednisone plus cabazitaxel or
mito-xantrone for metastatic castration-resistant prostate cancer
progressing after docetaxel treatment: A randomised open-label
trial. Lancet. 376:1147–1154. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kong R, Sun B, Jiang H, Pan S, Chen H,
Wang S, Krissansen GW and Sun X: Downregulation of nuclear
factor-kappaB p65 subunit by small interfering RNA synergizes with
gemcitabine to inhibit the growth of pancreatic cancer. Cancer
Lett. 291:90–98. 2010. View Article : Google Scholar
|
|
40
|
Yuan Z, Jiang H, Zhu X, Liu X and Li J:
Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through
inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on
triple-negative breast cancer. Biomed Pharmacother. 89:227–232.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xie B, Wan J, Chen X, Han W and Wang H:
Preclinical evaluation of a cabazitaxel prodrug using nanoparticle
delivery for the treatment of taxane-resistant malignancies. Mol
Cancer Ther. 19:822–834. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Meng F, Sun Y, Lee RJ, Wang G, Zheng X,
Zhang H, Fu Y, Yan G, Wang Y, Deng W, et al: Folate
receptor-targeted albumin nanoparticles based on microfluidic
technology to deliver cabazitaxel. Cancers (Basel). 11:112019.
View Article : Google Scholar
|
|
43
|
Ren T, Wang Q, Xu Y, Cong L, Gou J, Tao X,
Zhang Y, He H, Yin T, Zhang H, et al: Enhanced oral absorption and
anticancer efficacy of cabazitaxel by overcoming intestinal mucus
and epithelium barriers using surface polyethylene oxide (PEO)
decorated positively charged polymer-lipid hybrid nanoparticles. J
Control Release. 269:423–438. 2018. View Article : Google Scholar
|
